Taysha takes charge of a Rare Disease Gene Therapy for $5.5 M
Taysha Gene Therapies announced the acquisition of exclusive global rights to TSHA-120 from a leading patient advocacy group for an upfront payment of USD 5.5 million.
TSHA-120 is an intrathecally dosed AAV9 gene therapy designed to treat giant axonal neuropathy (GAN). Giant axonal neuropathy is a rare genetic disorder affecting over 2000 people in the US and Europe. It is a result of loss-of-function mutations in the gene coding for gigaxonin. It severely affects the peripheral as well as the central nervous system.
TSHA-120 has earlier received rare pediatric disease and orphan ...
